About AVT
Browse Articles
Customer Services

Original article

Modelling the interaction between danoprevir and mericitabine in the treatment of chronic HCV infection

Laetitia Canini, Jeremie Guedj, Anushree Chatterjee, Annabelle Lemenuel-Diot, Patrick F Smith, Alan S Perelson

Corresponding author name: Alan S Perelson
Corresponding author e-mail: asp@lanl.gov

Citation: Antiviral Therapy 2016; 21:297-306
doi: 10.3851/IMP3006

Date accepted: 26 October 2015
Date published online: 10 November 2015


Background: Modelling HCV RNA decline kinetics under therapy has proven useful for characterizing treatment effectiveness.

Methods: Here we model HCV viral kinetics (VK) in 72 patients given a combination of danoprevir, a protease inhibitor, and mericitabine, a nucleoside polymerase inhibitor, for 14 days in the INFORM-1 trial. A biphasic VK model with time-varying danoprevir and mericitabine effectiveness and Bliss independence for characterizing the interaction between both drugs provided the best fit to the VK data.

Results: The average final antiviral effectiveness of the drug combination varied between 0.998 for 100 mg three times daily of danoprevir and 500 mg twice daily of mericitabine and 0.9998 for 600 mg twice daily of danoprevir and 1,000 mg twice daily of mericitabine. Using the individual parameters estimated from the VK data collected over 2 weeks, we were not able to reproduce the low sustained virological response rates obtained in a more recent study where patients were treated with a combination of mericitabine and ritonavir-boosted danoprevir for 24 weeks.

Conclusions: This suggests that drug-resistant viruses emerge after 2 weeks of treatment and that longer studies are necessary to provide accurate predictions of longer treatment outcomes.


Copyright © 2022 Nucleus Holdings Ltd. Part of Nucleus Global.
Design and Technology by Nucleus Global
Company registration No. 321 0712 (England & Wales). Registered Office address: Admiral House 76-78 Old Street, London EC1V 9AZ.